Mechanistically, IGFBP2 stimulated the transcriptional activity of STAT3 on CXCL1, leading to an upregulation of CXCL1 expression in lung cancer cells and subsequently promoting gefitinib resistance. This evidence concerns the gene STAT3 and lung carcinoma.